ERBB2 and breast cancer: Trastuzumab deruxtecan (formerly DS-8201, T-DXd), has been approved to treat metastatic HER2+ BC patients with a cleavable linker containing a humanized anti-HER2 monoclonal antibody linked to topoisomerase I inhibitor [12, 13].